You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

ACEON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Aceon patents expire, and what generic alternatives are available?

Aceon is a drug marketed by Symplmed Pharms Llc and is included in one NDA.

The generic ingredient in ACEON is perindopril erbumine. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the perindopril erbumine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aceon

A generic version of ACEON was approved as perindopril erbumine by AUROBINDO PHARMA on November 10th, 2009.

  Try a Trial

Summary for ACEON
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 80
Patent Applications: 2,137
What excipients (inactive ingredients) are in ACEON?ACEON excipients list
DailyMed Link:ACEON at DailyMed
Drug patent expirations by year for ACEON
Paragraph IV (Patent) Challenges for ACEON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ACEON Tablets perindopril erbumine 2 mg, 4 mg and 8 mg 020184 1 2006-06-06

US Patents and Regulatory Information for ACEON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-001 Dec 30, 1993 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-002 Dec 30, 1993 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-003 Dec 30, 1993 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ACEON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-002 Dec 30, 1993 ⤷  Try a Trial ⤷  Try a Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-002 Dec 30, 1993 ⤷  Try a Trial ⤷  Try a Trial
Symplmed Pharms Llc ACEON perindopril erbumine TABLET;ORAL 020184-003 Dec 30, 1993 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ACEON

See the table below for patents covering ACEON around the world.

Country Patent Number Title Estimated Expiration
Canada 1341196 PROCEDE DE PREPARATION D'IMINO DIACIDES SUBSTITUES (PROCESS FOR THE PREPARATION OF SUBSTITUTED IMINO DIACIDS) ⤷  Try a Trial
Argentina 240949 PROCEDIMIENTO PARA PREPARAR DERIVADOS DE ACIDO N-(AMINOALCANOIL)-AZA-BICICLOCARBOXILICO ⤷  Try a Trial
Japan H0132239 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.